The estimated Net Worth of Patrick Baeuerle is at least $4.13 Milión dollars as of 8 September 2021. Dr Baeuerle owns over 11,000 units of Cullinan Oncology stock worth over $197,780 and over the last 6 years he sold CGEM stock worth over $3,192,346. In addition, he makes $737,928 as Co-Founder & Acting Chief Scientific Officer of Biologics at Cullinan Oncology.
Sign up
Dr D CGEM stock SEC Form 4 insiders trading
Dr has made over 4 trades of the Cullinan Oncology stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,000 units of CGEM stock worth $47,300 on 8 September 2021.
The largest trade he's ever made was selling 116,929 units of Cullinan Oncology stock on 20 December 2019 worth over $1,796,029. On average, Dr trades about 18,859 units every 52 days since 2019. As of 8 September 2021 he still owns at least 11,000 units of Cullinan Oncology stock.
You can see the complete history of Dr Baeuerle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Patrick A. Baeuerle Ph.D. biography
Dr. Patrick A. Baeuerle Ph.D. is the Co-Founder & Acting Chief Scientific Officer of Biologics at Cullinan Oncology.
What is the salary of Dr D?
As the Co-Founder & Acting Chief Scientific Officer of Biologics of Cullinan Oncology, the total compensation of Dr D at Cullinan Oncology is $737,928. There are no executives at Cullinan Oncology getting paid more.
How old is Dr D?
Dr D is 63, he's been the Co-Founder & Acting Chief Scientific Officer of Biologics of Cullinan Oncology since . There are no older and 7 younger executives at Cullinan Oncology.
What's Dr D's mailing address?
Patrick's mailing address filed with the SEC is C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Insiders trading at Cullinan Oncology
Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke a Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.
What does Cullinan Oncology do?
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
What does Cullinan Oncology's logo look like?
Complete history of Dr Baeuerle stock trades at Harpoon Therapeutics, TCR2 Therapeutics a Cullinan Oncology
Cullinan Oncology executives and stock owners
Cullinan Oncology executives and other stock owners filed with the SEC include:
-
Dr. Patrick A. Baeuerle Ph.D.,
Co-Founder & Acting Chief Scientific Officer of Biologics -
Owen P. Hughes Jr.,
Strategic Advisor -
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.,
Chief Medical Officer -
Steve Andre,
Chief HR Officer -
Rose Weldon,
VP of Communications -
Kerry Whalen,
Sr. Director of Preclinical & Early Devel. -
Dr. Jennifer Michaelson Ph.D.,
Chief Devel. Officer of Biologics -
Leigh Zawel Ph.D.,
Chief Scientific Officer of Small Molecules -
Corinne Savill Ph.D.,
Acting Chief Bus. Officer -
Raymond T. Keane,
Chief Legal Officer & Sec. -
Nate Nguyen,
Director of Accounting & Controller -
Jeffrey Trigilio,
CFO & Treasurer -
Nadim Ahmed,
Pres, CEO & Director -
Vision Scs Jovan Embiricos ...,
-
Anthony Rosenberg,
-
Morana Jovan Embiricos,
10% owner -
Jacquelyn L Sumer,
Chief Legal Officer -
Nadim Ahmed,
President and CEO -
Raymond T Keane,
Chief Legal Officer -
Jon Marc Wigginton,
Chief Medical Officer -
Owen Hughes,
President and CEO -
Leigh Zawel,
See Remarks -
Morana Globeways Holdings L...,
-
Ansbert Gadicke,
Director -
Oncology Impact Fund L.P.On...,
-
Oncology Impact Fund L.P.On...,
-
Partners L P/Ilbiotechnolog...,
-
Jennifer Michaelson,
Chief Scientific Officer -
David P. Ryan,
-
Patrick Baeuerle,
Chief Scientific Officer -
Bioscience I 2017 Ltd Jovan...,
-
Stephen W Webster,
-
Thomas Ebeling,
-
Anne Marie Martin,
-
Jeffrey Trigilio,
Chief Financial Officer -
Jeffrey Alan Jones,
Chief Medical Officer -
Corrine Savill,
Chief Business Officer -
Mary Kay Fenton,
Chief Financial Officer -
David D. Meek,
-
Mary Thistle,